J&J Chief Patent Attorney Shares Views on IP Waiver for COVID-19 Vaccines
shot by IP News Shots / 5:19 pm on 23 April, 2021
The chief patent attorney of Johnson & Johnson expressed his views on the petition for intellectual property (IP) waiver for COVID-19 vaccines, at a webinar. The Chief said that waiving the IP rights for the vaccines would result in safety issues which can be avoided by voluntary licensing. He went on to state that IP owning companies can opt to provide licenses to manufacturers that are capable of hosting the right infrastructure for the process which is not possible when the IP rights are waived and everyone is allowed to manufacture the vaccines.
Read More at: https://www.law360.com/articles/1375715/j-j-s-chief-patent-atty-says-covid-ip-waiver-won-t-work
Industry: Healthcare Equipment & Supplies, Pharmaceuticals